Archives: Agenda

• Defining clear roles between sponsors and vendors in hybrid models to avoid overlap
• Facilitating seamless exchange of operational metrics and risk indicators across vendors ensuring proactive oversight and responsive decisions
• Implementing risk-based oversight to focus on what matters most eliminating redundancies while enhancing quality
• Designing governance frameworks that accelerate decision making while ensuring continuous inspection readiness

• Understand when oversight creates real value versus when it’s just a checkbox
• Hear what vendors wish sponsors would stop doing (and vice versa)
• Explore 3 key pillars of oversight: relationship management, performance management, and quality & compliance
• Learn how industry leaders are navigating the hardest parts of risk-based oversight: scalability, regulatory complexity, and the resource-intensive nature of the work
• Walk away with practical insights you can apply to your own oversight plan — whether you’re building one from scratch or maturing an existing program

Moderator: Peter Haessig, Head of Client Partnerships, Diligent Pharma

• How well‑designed digital measures deliver measurable ROI in clinical trials by reducing missing data, improving statistical power, accelerating timelines, and preventing costly trial rework or failure
• How an end‑to‑end Wearable Sensor CRO delivery model integrates scientific strategy, operational oversight, and analytics to consistently produce regulatory‑ready datasets
• Real‑world case examples showing how proactive compliance monitoring and fit‑for‑purpose algorithms dramatically improve data completeness and statistical power
• The critical role of disease‑specific digital endpoint design versus off‑the‑shelf wearable algorithms in capturing meaningful treatment effects
• Practical guidance for clinical operations and outsourcing teams on reducing sponsor burden while scaling wearable technologies across global trials

• Demonstrating good faith compliance with emerging expectations
• Documenting rationale and regulatory intelligence in trial files
• Engaging with FDA proactively to validate regulatory strategy

• Why be a sponsor of choice in the ever changing landscape
• What we do to elevate our site partnerships
• Always keep pushing through curiosity to drive innovation to ensure the health of our industry

• Abuse Liability & PK Timeline Considerations
• Planned vs. Actual Study Execution Timelines
• Operational Capabilities that Enable Timeline Control

• What are the biggest barriers preventing patients from enrolling in clinical trials today?
• How can sites and sponsors improve recruitment strategies to reach the right patients faster?
• What role can digital tools, data, and patient engagement play in accelerating enrollment?
• How can collaboration between sponsors, CROs, sites, and patient communities transform recruitment outcomes?

For emerging biotechs and biopharmas, the path from early-phase trials to global development is filled with operational and strategic risk. Increasing protocol complexity, fragmented vendor landscapes, and varying regulatory expectations add layers of uncertainty. In this talk, Adam Marsh will outline key inflection points where risk can be proactively mitigated, from study design through execution and scale-up. Attendees will leave with a clearer framework for reducing execution risk while enabling faster, more confident decision-making.